Unknown

Dataset Information

0

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.


ABSTRACT: The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

SUBMITTER: Merseburger AS 

PROVIDER: S-EPMC7515768 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularl  ...[more]

Similar Datasets

| S-EPMC5396399 | biostudies-literature
| S-EPMC5856703 | biostudies-literature
| S-EPMC4647143 | biostudies-literature
| S-EPMC5066115 | biostudies-literature
| S-EPMC6375453 | biostudies-literature
| S-EPMC5040928 | biostudies-literature
| S-EPMC5976948 | biostudies-literature
| S-EPMC10665906 | biostudies-literature
| S-EPMC8481908 | biostudies-literature
| S-EPMC4462531 | biostudies-literature